Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 239

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 239
---
 therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components of our strategy for achieving this goal include: (for details of our strategy, See “Business Overview — Our Strategy”) •Developing therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas; •Selectively expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical needs; •Collaborating with leading academic institutions and CROs; •Expanding our in -housepharmaceutical development center; •Leveraging our management’s expertise, experience and commercial networks; •Obtaining and leveraging government grants to fund project development. We have devoted a substantial portion of the proceeds from our offerings, to our Lead Projects. Our Lead Projects are ALS -4and SACT -1. In March 2023, we announced that we completed the Pre -INDdiscussions with the US FDA on ALS -4. In March 2023, we also announced the completion of the End of Phase 1 (EOP1) meeting of SACT -1with the US FDA. The FDA generally agreed with the chemistry -manufacturing-control(CMC) strategy and our proposed clinical development plan for SACT -1Phase 1/2 trials. The timing and scope of advancing both ALS -4Phase 2 clinical trials and SACT -1Phase 1/2 trials will be contingent upon securing appropriate collaborative partnerships and adequate funding resources. The Company is actively seeking strategic collaborators who can provide both financial support and clinical expertise to advance these promising therapeutic programs. During the second quarter of 2023, the Company made a decision to streamline its operations by terminating clinic services and suspending non -leadR&D projects. This measure is aimed at optimizing the allocation of our resources and focusing our efforts on advancing our lead projects, which hold the most promise for commercial success and beneficial impact. This decision aligns with our commitment to enhance shareholder value and effectively drive our core objectives forward in the competitive landscape. Prior to March 2017, the Company had pursued passive healthcare related investments in early -stagecompanies primarily in the United States. However, we have since ceased pursuing further passive investment operations and intend to exit all such portfolio investments over an appropriate timeframe to focus resources on our current business. Lead Projects We are operating and managing the development of our drug candidates through various subsidiaries. Each candidate is being researched in a subsidiary with a medical/scientific area of focus related to the drug candidate in development